Metsera
Metsera is a clinical-stage biotechnology company dedicated to reducing the burdens of obesity through innovative therapies. Their mission is to develop trusted, convenient, and affordable medicines that can scale to meet the global health challenge of obesity. They focus on engineering, developing, manufacturing, and commercializing a new generation of potent, ultra-long acting, scalable nutrient-stimulated hormone (NuSH) therapies for obesity and related diseases, with a comprehensive approach spanning peptide engineering, science, clinical development, and manufacturing.
Industries
Nr. of Employees
small (1-50)
Metsera
3 World Trade Center, 175 Greenwich St, New York, NY 10007
Products
Next Generation Medicines
Metsera is developing a new generation of oral and injectable therapies targeting obesity and metabolic diseases, utilizing a proprietary library of peptides and monoclonal antibodies.
MET-097
A novel, potential once-monthly injectable GLP-1 receptor agonist being developed for obesity and metabolic diseases.
MET-097
A novel, potential once-monthly injectable GLP-1 receptor agonist being developed for obesity and metabolic diseases.
MET-097
A novel, potential once-monthly injectable GLP-1 receptor agonist being developed for obesity and metabolic diseases.
Next-Generation Medicines
A portfolio of oral and injectable therapies targeting obesity and metabolic diseases, leveraging a proprietary library of peptides and monoclonal antibodies.
Next-Generation Medicines
A portfolio of oral and injectable therapies targeting obesity and metabolic diseases, leveraging a proprietary library of peptides and monoclonal antibodies.
Next Generation Medicines
Metsera is developing a new generation of oral and injectable therapies targeting obesity and metabolic diseases, utilizing a proprietary library of peptides and monoclonal antibodies.
MET-097
A novel, potential once-monthly injectable GLP-1 receptor agonist being developed for obesity and metabolic diseases.
MET-097
A novel, potential once-monthly injectable GLP-1 receptor agonist being developed for obesity and metabolic diseases.
MET-097
A novel, potential once-monthly injectable GLP-1 receptor agonist being developed for obesity and metabolic diseases.
Next-Generation Medicines
A portfolio of oral and injectable therapies targeting obesity and metabolic diseases, leveraging a proprietary library of peptides and monoclonal antibodies.
Next-Generation Medicines
A portfolio of oral and injectable therapies targeting obesity and metabolic diseases, leveraging a proprietary library of peptides and monoclonal antibodies.